Yubo International Biotech (OTCMKTS:YBGJ – Get Rating) and CONMED (NYSE:CNMD – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.
This is a summary of recent ratings and recommmendations for Yubo International Biotech and CONMED, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Yubo International Biotech||0||0||0||0||N/A|
CONMED has a consensus price target of $106.00, indicating a potential upside of 9.70%. Given CONMED’s higher possible upside, analysts clearly believe CONMED is more favorable than Yubo International Biotech.
Volatility and Risk
Insider & Institutional Ownership
13.7% of Yubo International Biotech shares are owned by institutional investors. 56.5% of Yubo International Biotech shares are owned by company insiders. Comparatively, 4.9% of CONMED shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Yubo International Biotech and CONMED’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Yubo International Biotech||$1.24 million||9.05||-$1.54 million||N/A||N/A|
|CONMED||$1.01 billion||2.91||$62.54 million||($2.95)||-32.76|
CONMED has higher revenue and earnings than Yubo International Biotech.
This table compares Yubo International Biotech and CONMED’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Yubo International Biotech||-460.24%||N/A||-40.54%|
CONMED beats Yubo International Biotech on 7 of the 11 factors compared between the two stocks.
About Yubo International Biotech
Yubo International Biotech Ltd. engages in the supply of products that process, store and administer therapeutic doses of endometrial stem cells for treatment of disease and injuries. Its products include Life Shinkansen Liquid Dressing and Life Shinkansen Spray Dressing. The company was founded by Lawrence A. Minkoff on February 22, 1991 and is headquartered in Beijing, China.
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Receive News & Ratings for Yubo International Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yubo International Biotech and related companies with MarketBeat.com's FREE daily email newsletter.